Reneo Pharmaceuticals, Inc. (RPHM): Price and Financial Metrics
GET POWR RATINGS... FREE!
RPHM Stock Price Chart Interactive Chart >
RPHM Price/Volume Stats
|Current price||$2.08||52-week high||$12.78|
|Prev. close||$2.12||52-week low||$1.92|
|Day high||$2.16||Avg. volume||58,597|
|50-day MA||$2.57||Dividend yield||N/A|
|200-day MA||$5.97||Market Cap||50.87M|
Reneo Pharmaceuticals, Inc. (RPHM) Company Bio
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Most Popular Stories View All
RPHM Latest News Stream
|Loading, please wait...|
RPHM Latest Social Stream
View Full RPHM Social Stream
Latest RPHM News From Around the Web
Below are the latest news stories about Reneo Pharmaceuticals Inc that investors may wish to consider to help them evaluate RPHM as an investment opportunity.
IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will be hosting a fireside chat and participating in one-on-one investor meetings at SVB Leerink’s Virtual Global Healthcare Conference taking place February 14-18, 2022. Presentation details are as follows: Date: Friday, F
IRVINE, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced changes to its Board of Directors. Paul W. Hoelscher, Executive Vice President, Chief Financial Officer of Horizon Therapeutics plc, has been appointed to the Board and will serve as chair of the Audit Committee. In conjunction wit
We can readily understand why investors are attracted to unprofitable companies. For example, although...
The market’s giants grab all the headlines, with their huge market caps and 4-figure share prices, making it easy to overlook that there are plenty of other opportunities in the stock market for investors willing to take a deeper look into the background. So let’s come up with a profile for lesser-known stocks with high potential. To start with, we should look for stocks with a Strong Buy from the analyst consensus – these are the equities that have broad agreement from Wall Street on the qualit
H.C. Wainwright analyst Edwin Zhang initiated coverage with a Buy rating on Reneo Pharmaceuticals (RPHM – Research Report) today and set a price target of $28.00. The company's shares closed last Monday at $6.88, close to its 52-week low of $5.95. According to TipRanks.com, Zhang has 0 stars on 0-5 stars ranking scale with an average return of -22.9% and a 11.1% success rate. Zhang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Calliditas Therapeutics, and Logicbio Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Reneo Pharmaceuticals with a $26.50 average price target.
RPHM Price Returns